Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | GABRA1 | P14867 | 7/20 | 0.48 |
| ▸ | GABRG2 | P18507 | 7/20 | 0.48 |
| ▸ | GABRB3 | P28472 | 7/20 | 0.48 |
| ▸ | GABRA5 | P31644 | 7/20 | 0.48 |
| ▸ | GABRA3 | P34903 | 7/20 | 0.48 |
| ▸ | GABRA2 | P47869 | 7/20 | 0.48 |
| ▸ | GABRA4 | P48169 | 7/20 | 0.48 |
| ▸ | GABRA6 | Q16445 | 7/20 | 0.48 |
| ▸ | GABRP | O00591 | 6/20 | 0.48 |
| ▸ | GABRD | O14764 | 6/20 | 0.48 |
| ▸ | GABRB1 | P18505 | 6/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 6/20 | 0.48 |
| ▸ | GABRE | P78334 | 6/20 | 0.48 |
| ▸ | GABRG1 | Q8N1C3 | 6/20 | 0.48 |
| ▸ | GABRG3 | Q99928 | 6/20 | 0.48 |
| ▸ | GABRQ | Q9UN88 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28042930 | 0.84 | TSHR (0.60) | CYP1A2LMNACYP3A4ALDH1A1NPC1 | |
| SCHEMBL31172628 | 0.82 | CYP1A2 (0.55) | CYP1A2LMNAGABRA1GABRG2GABRB3 | |
| SCHEMBL82426 | 0.82 | CYP1A2 (0.55) | CYP1A2LMNAGABRA1GABRG2GABRB3 | |
| SCHEMBL1971939 | 0.81 | MAPK1 (0.61) | CYP1A2LMNACYP3A4MAOAGABRA1 | |
| SCHEMBL10003611 | 0.81 | CYP1A2 (0.53) | CYP1A2LMNACYP3A4GABRA1GABRG2 | |
| SCHEMBL29637478 | 0.81 | MAPK1 (0.61) | CYP1A2LMNACYP3A4MAOAGABRA1 | |
| SCHEMBL229176 | 0.81 | CA12 (0.55) | CYP1A2LMNAGABRA1GABRG2GABRB3 | |
| SCHEMBL31359497 | 0.80 | MAPK1 (0.65) | CYP1A2LMNACYP3A4GABRA1GABRG2 | |
| SCHEMBL721291 | 0.80 | MAPK1 (0.65) | CYP1A2LMNACYP3A4GABRA1GABRG2 | |
| SCHEMBL14288423 | 0.80 | POLB (0.49) | CYP1A2LMNACYP3A4MAOAGABRA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 164 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606544-B2 | JAK1 selective kinase inhibitor | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| EP-3956322-B1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-05-14 | — | — | EP | disclosed |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-04-22 | — | — | US | disclosed |
| EP-3651752-B1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMA (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3568390-B1 | SMALL MOLECULE ACTIVATORS OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) AND USES THEREOF | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2024-03-06 | — | — | EP | disclosed |
| CN-113710664-B | JAK1 selective kinase inhibitors | 迪哲(江苏)医药股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2023-11-07 | — | — | US | disclosed |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-09-14 | — | — | US | disclosed |
| US-20040127477-A1 | Heterocyclic glycyl beta-alanine derivatives | G. D. SEARLE & CO. (US) | 2004-07-01 | — | — | US | disclosed |
| US-6756378-B2 | BENZYL -UREA, -THIOUREA, OR -GUANIDINE DERIVATIVES THAT INHIBIT THE BINDING OF LIGANDS TO ALPHA 4 BETA 1 INTEGRIN (VLA-4) | PHARMACOPEIA DRUG DISCOVERY, INC. | 2004-06-29 | — | — | US | disclosed |
| WO-2004014904-A1 | ANTIPROLIFERATIVE 2-(HETEROARYL)-AMINOTHIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE | PFIZER INC. (US) | 2004-02-19 | — | — | WO | disclosed |
| US-6689754-B1 | PIPERIDINE OR PYRIDINE DERIVATIVES; ALPHA V BETA 3 INTEGRIN ANTAGONISTS | G. D. SEARLE & CO. | 2004-02-10 | — | — | US | disclosed |
| US-20030078249-A1 | VLA-4 inhibitor compounds | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-04-24 | — | — | US | disclosed |
| CN-1391473-A | VLA-4 inhibitor compounds | DAIICHI SEIYAKU CO (JP) | 2003-01-15 | — | — | CN | disclosed |
| EP-1189612-A1 | VLA-4 INHIBITOR COMPOUNDS | Daiichi Pharmaceutical Co., Ltd. (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-1070060-A1 | HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS | G.D. Searle & Co. (US) | 2001-01-24 | — | — | EP | disclosed |
| WO-2001000206-A1 | VLA-4 INHIBITOR COMPOUNDS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-01-04 | — | — | WO | disclosed |
| WO-1999052896-A1 | HETEROCYCLIC GLYCYL BETA-ALANINE DERIVATIVES AS VITRONECTIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078249-A1 | VLA-4 inhibitor compounds | VCAM1, ICAM1, ITGA4 | CYP1A2 2573/4885LMNA 2308/4885CYP3A4 594/4885 |
| US-20040127477-A1 | Heterocyclic glycyl beta-alanine derivatives | ITGB3, ITGAL, ITGB1 | CYP1A2 2704/4885LMNA 972/4885CYP3A4 1724/4885 |
| US-12606544-B2 | JAK1 selective kinase inhibitor | JAK1, JAK2, JAK3 | CYP1A2 1967/4885LMNA 4435/4885CYP3A4 2603/4885 |
| US-11806337-B2 | Small molecule activators of nicotinamide phosphoribosyltransferase (NAMPT) and uses thereof | NAMPT, NAPRT, NNT | CYP1A2 3759/4885LMNA 2516/4885CYP3A4 3770/4885 |
| US-20230286907-A1 | CARBOXAMIDES AS MODULATORS OF SODIUM CHANNELS | TRPV1, SCN2A, SCN10A | CYP1A2 3138/4885LMNA 2874/4885CYP3A4 2128/4885 |
| US-12281057-B2 | Carboxamides as modulators of sodium channels | TRPV1, SCN2A, SCN10A | CYP1A2 3138/4885LMNA 2874/4885CYP3A4 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.